Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis

Tao Fu, Founder and Chief Executive Officer of Attovia

“These results exceeded our expectations, building on the compelling Week 4 findings and providing strong emerging evidence supporting the key pillars of our differentiated target product profile: rapid, deep, and durable itch relief, the potential for quarterly dosing, and a favorable safety profile. We are particularly encouraged by the remarkable depth and durability of itch relief observed in patients with CP, as well as the sustained improvements in both itch and skin lesions in patients with high-itch AD—all following a single subcutaneous dose. Combined with sustained IL-31 suppression through Week 12, these findings further strengthen our confidence in ATTO-1310’s potential to become a next-generation IL-31 therapy for patients suffering from chronic itch conditions. We look forward to advancing ATTO-1310 into two Phase 2 trials in the first half of 2027.”

Brian Kim, MD, MTR, FAAD, Vice President and Chief Biotechnology Officer at Northwell Health, Inaugural Robin and Jack Ross Chair and Professor of Bioelectronic Medicine and Neuroimmunology at the Feinstein Institutes for Medical Research

“CPUO is one of the most common conditions I see in my clinic, yet despite affecting an estimated two to five million adults in the U.S., there are still no FDA-approved treatments. These patients, many of whom are older adults, suffer from relentless itch that profoundly impacts their quality of life and is often associated with anxiety and depression. ATTO-1310’s strategy of targeting the IL-31 ligand rather than its receptor offers a potentially differentiated approach to achieving robust itch relief while reducing the risk of the dermatitis flares observed with receptor blockade. The rapid onset, remarkable depth, and sustained durability of itch relief following a single dose of ATTO-1310 in this Phase 1b study are particularly impressive. These results give me great optimism that we may finally be approaching a treatment breakthrough for the millions of patients suffering from CPUO.”

Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences

“Itch is the most burdensome symptom of atopic dermatitis, profoundly affecting patients’ quality of life and driving treatment decisions. Up to one-third of adults with AD experience severe itch despite having only mild-to-moderate skin lesions, a disease burden often underestimated by traditional severity measures. These patients remain underserved, with no approved systemic therapy. Given the central role of IL-31 in driving itch, a highly effective, long-acting biologic targeting this pathway could represent an important advance in AD treatment. The Phase 1b results with ATTO-1310 are particularly encouraging, demonstrating sustained improvements in both itch and skin lesions following a single dose, and provide a compelling rationale for further evaluation in Phase 2 studies.”